See All Authors »

James Brumley

Contributing Writer
Kiplinger.com

James Brumley is a former stock broker, registered investment adviser and Director of Research for an options-focused newsletter. He's now primarily a freelance writer, tapping more than a decade's worth of broad experience to help investors get more out of the market. With a background in technical analysis as well as fundamental analysis, James touts stock-picking strategies that combine the importance of company performance with the power of stock-trade timing. He believes this dual approach is the only way an investor has a shot at consistently beating the market. James' work has appeared at several websites including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multi-pronged approach to investing.

Latest Features

SLIDE SHOW
September 2018

7 Best Biotech Stocks for Investors Who Hate Risk

Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the ...

See More From: Stocks & Bonds

SLIDE SHOW
September 2018

10 Companies Already Hurt by President Trump's Tariffs

If steep tariffs on goods imported into the United States are only part of a negotiating tactic from President Donald Trump, he certainly has committed to his bluff. Trump’s tariffs – the first of ...

See More From: Stocks & Bonds

SLIDE SHOW
September 2018

12 Top Stock Picks to Shield Your Portfolio

The stock market is a running milestone. We’re currently in the longest-ever bull market – a fact that became official on Wednesday, Aug. 22, when it became 3,453 days old. Some have shrugged off the ...

See More From: Stocks & Bonds

SLIDE SHOW
September 2018

49 Companies Amazon Could Destroy (And 1 It Already Has)

You would think e-commerce and cloud computing giant Amazon.com (AMZN), after 20 years of unfettered growth, would have run out of room to pump up its top line. But the company continues to choose new ...

See More From: Stocks & Bonds

SLIDE SHOW
August 2018

7 Struggling Companies in Retreat Mode

The economy's as strong as it's been in years, and corporate earnings have collectively been even better than expected. By all accounts, companies—all companies—should be thriving. And most are. Not ...

See More From: Stocks & Bonds

Stock Watch
August 2018

Does Apple’s $1 Trillion Benchmark Even Matter?

Wall Street collectively pointed and stared at the big, round number. But experts don’t agree on what it means for AAPL stock.

See More From: Stock Watch

SLIDE SHOW
August 2018

7 Tesla (TSLA) Risks That Investors Can’t Ignore

Give credit where it’s due. Tesla Inc. (TSLA, $300.84) CEO Elon Musk, through sheer willpower and persistence, has mainstreamed the idea of electric vehicles. EVs were a fringe project taken on by only ...

See More From: Investor Psychology

SLIDE SHOW
July 2018

10 of the Market’s Most Shorted Stocks

When can negativity be used for something positive? Well, in the market, a quick look at the most shorted stocks could unearth potential. The typical investor’s approach to the market is buying low, ...

See More From: Stocks & Bonds

SLIDE SHOW
July 2018

7 Former Dow Jones Stocks That Survived "The Boot"

Once-great industrial giant General Electric (GE) was removed as a constituent of the Dow Jones Industrial Average in June 2018. Although GE was a component of the blue-chip index for 110 years, time finally ...

See More From: Stocks & Bonds

SLIDE SHOW
July 2018

10 Cancer-Fighting Health Care Stocks to Buy

Cancer. The mere mention of the word can drudge up discomfort, as most everyone knows it’s second only to heart disease when it comes to claiming lives. Unlike heart disease, though, cancer is difficult ...

See More From: Stocks & Bonds

SLIDE SHOW
July 2018

10 Top Nasdaq Stocks to Buy Now

Not all that long ago, a Nasdaq listing of a stock was met with a bit of derision. While it wasn’t as lowly as the “pink sheets,” the up-and-coming exchange – which was more of a telecommunications ...

See More From: Stocks & Bonds

SLIDE SHOW
July 2018

10 Underappreciated Biotech Stocks to Buy

When investors think of biotech stocks, visions of Amgen (AMGN) and Gilead (GILD) tend to dance in their heads. These companies aren’t just among the biggest in the business – they’re also a couple ...

See More From: Stocks & Bonds

Stock Watch
June 2018

Amazon.com (AMZN) Buys PillPack: No Clear Winner, One Very Clear Loser

Amazon's newest move into the online pharmacy business will have significant ripple effects

See More From: Stock Watch

Stock Watch
June 2018

Doubt Nvidia (NVDA) at Your Own Peril

Besides valuation concerns, what (if anything) could slow NVDA stock down? If such a speed bump is out there, nobody has seen it yet.

See More From: Stock Watch

SLIDE SHOW
June 2018

10 Best Energy Stocks for the Rest of 2018

The more-than-doubling of crude oil prices over the past couple of years has been a difficult rally to trust. Energy companies still aren’t exactly highly disciplined outfits despite the pain of overproduction ...

See More From: Stocks & Bonds

SLIDE SHOW
May 2018

The 18 Best Stocks to Buy for the Rest of 2018

We’re almost to the halfway point of the year, and so far … not so good. The market has disappointed, and the investing landscape has shifted drastically in a very short time. Thus, investors looking ...

See More From: Stocks & Bonds

SLIDE SHOW
May 2018

10 Top Health-Care Stocks That Never Break a Sweat

Health-care stocks – and pharmaceutical makers in particular – recently dodged a bullet when President Donald Trump unveiled a relatively benign overhaul to the nation’s health-care system with the ...

See More From: Stocks & Bonds

Show More Stories